Edition:
India

Novartis Says Phase III PREVENT Study Met Primary Endpoint For Patients With Axial Spondyloarthritis


Tuesday, 17 Sep 2019 

Sept 17 (Reuters) - Novartis AG ::NOVARTIS COSENTYX® POSITIVE 16-WEEK PREVENT RESULTS ADVANCE POTENTIAL NEW INDICATION FOR PATIENTS WITH AXIAL SPONDYLOARTHRITIS.PHASE III PREVENT STUDY MET 16-WEEK PRIMARY ENDPOINT OF ASAS40 IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA).ALL SECONDARY ENDPOINTS WERE ALSO MET.NOVARTIS HAS SUBMITTED TO EMA FOR APPROVAL IN NR-AXSPA, WHICH WOULD BE FOURTH INDICATION FOR COSENTYX.52-WEEK DATA FROM PREVENT STUDY, TO SUPPORT FDA SUBMISSION, ARE EXPECTED LATER IN YEAR.